Participated · Equity · Jun 2026

Beren Therapeutics P.B.C. is a founder-led biotech focused on discovery, development, and commercialization of cyclodextrin-based therapies that address defective intracellular cholesterol trafficking. Its lead program, adrabetadex, is under Priority Review by the U.S. FDA with a PDUFA target action date of November 17, 2026, and has been studied in clinical trials and expanded access programs since 2021. The company has built patient access and family support initiatives and intends to prepare for a potential U.S. commercial launch if adrabetadex is approved. Beren describes itself as a public benefit company that integrates patient, caregiver, clinician, and health-system needs into development and access planning. The recent $300 million financing package is intended to support commercial readiness and long-term care infrastructure and aims to position the company to be financially self-sustaining through potential commercialization. Beren is headquartered in Thousand Oaks, California.

Led · Series A · Aug 2024

Seed Therapeutics applies a proprietary platform to create molecular glue degraders that induce targeted protein degradation in cancer and other diseases. Its lead program, ST-01156, is a first-in-class degrader aimed at RBM39 and has just received FDA clearance of its Investigational New Drug application. The company intends to initiate first-in-human clinical trials for ST-01156 in the first quarter of 2026, marking its transition to a clinical-stage enterprise. Beyond the newly announced financing, Seed has accumulated nearly $60 million through equity, upfront, and milestone payments stemming from strategic partnerships with Eli Lilly and Eisai. These resources, combined with the latest capital infusion, are expected to support advancement of ST-01156 and expansion of a broader pipeline of molecular glue degraders. Seed Therapeutics’ management highlights the combined strength of venture financing and collaboration payments as key to sustaining its clinical and discovery programs.

Led · Equity · Mar 2024

C2N Diagnostics develops the Precivity portfolio of blood tests and high-resolution LC‑MS/MS biomarker services to aid diagnosis and management of Alzheimer’s disease. Its Precivity tests detect amyloid and tau biomarkers and have been used in over 150 research studies, with more than 30,000 Precivity-related biomarker measures reported. C2N operates a CLIA‑certified, CAP‑accredited laboratory in St. Louis and provides testing as laboratory-developed tests (LDTs), with access via a U.S. network of over 700 patient service centers and 13,000 mobile phlebotomists. The company plans to build a fully automated, standardized, high-resolution LC‑MS clinical analyzer and accompanying diagnostic kits to enable decentralized, local deployment of its assays worldwide. The global scalability project will accommodate multiple assays tracking amyloid and tau pathology and provide a framework to add future neuropathology assays. C2N has established partnerships to expand access to Precivity testing, including a multi-year exclusive agreement with Unilabs for Europe and a non-exclusive agreement with Mayo Clinic Laboratories. The company received an investment of up to $7.025 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator to support the LC‑MS platform effort. C2N Diagnostics develops and provides high-resolution mass spectrometry-based biomarker services and the Precivity™ blood tests intended for use in patients with cognitive impairment. Its Precivity tests are designed to help healthcare providers determine Alzheimer’s disease pathology and aid medical management and treatment decisions. C2N assays have been used in over 150 Alzheimer’s disease and other research studies worldwide, and over 15,000 Precivity-related biomarker measures have been reported in peer-reviewed publications. The company collaborates with pharmaceutical and biotech companies, leading academic institutions, the National Institute on Aging, the Alzheimer’s Association, and other non-profits and consortiums to support clinical trials and research. With Eisai’s investment, C2N plans to scale up and expand the availability, accessibility, and use of its high-performance blood biomarker tests for early diagnosis of Alzheimer’s disease in the U.S. The company also acknowledges support from the National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer’s Association. C2N Diagnostics develops and commercializes blood-based biomarkers for Alzheimer’s disease, including the PrecivityAD® test and the next-generation PrecivityAD2™. The company uses high-resolution mass spectrometry to provide laboratory services and products that support clinical decision-making, clinical trials, and research into neurodegeneration. C2N plans to use new capital to advance PrecivityAD2™, run additional clinical studies to build real-world evidence, and expand global market access and medical education. The company will also invest in biomarker pipeline development, infrastructure growth, and workflow efficiencies to prepare for higher testing volumes and commercial demand. C2N recently marked the two-year anniversary of the PrecivityAD® launch and says the test is the first widely accessible blood test to assist healthcare providers with Alzheimer’s diagnosis. The company acknowledges support from funders including the National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, and the Alzheimer’s Association. C2N Diagnostics is commercializing the APTUS™ platform, a panel of blood tests to enable early detection and monitoring of neurodegenerative disorders. Its lead APTUS-Aβ™ test combines mass spectrometry quantification of plasma Aβ42/Aβ40, ApoE status, and age to predict brain amyloidosis. The APTUS-Aβ test received Breakthrough Device Designation from the FDA in early 2019 and is being positioned for clinical use under CLIA. C2N was formed by scientists from Washington University School of Medicine in St. Louis and LifeTech Research and operates a CLIA-certified clinical laboratory facility in St. Louis, Missouri. The company also developed a portfolio of anti-tau antibodies and formed a global partnership with AbbVie in March 2015 to develop and commercialize those assets. With the new funding, C2N plans to establish a premium quality patient testing service, pursue an IVD label with the FDA, and seek reimbursement from CMS while expanding its global growth and diagnostic pipeline.

Participated · Series C · Nov 2022

Casma Therapeutics is engineering therapies that target the cell’s autophagy and lysosomal systems to eliminate disease-causing cellular waste. Its lead program, CSM-101, is an orally bioavailable, brain-penetrant small-molecule agonist of the lysosomal ion channel TRPML1 intended to restore lysosomal function and provide disease-modifying benefit in Parkinson’s disease. In preclinical studies, CSM-101 demonstrated high CNS exposure, reduced toxic lipid accumulation, lowered neuroinflammation, decreased alpha-synuclein levels, and preserved dopaminergic neurons in Gaucher-associated and idiopathic Parkinson’s models. The company is first pursuing Gaucher’s patients who develop Parkinson’s, with plans to expand into broader GBA-associated and idiopathic PD populations. Beyond CSM-101, Casma is building a pipeline that applies its lysosomal and autophagy platform to neurodegeneration, oncology, inflammation, and metabolic disorders. Casma recently secured $7.6 million in non-dilutive grant funding to complete biomarker development and IND-enabling studies for CSM-101, positioning the candidate for first-in-human trials. No additional financial metrics or revenue figures were disclosed.

Participated · Series A · Jan 2022

Ractigen Therapeutics, founded in 2017 by RNAa pioneers Dr. Long-Cheng Li, Dr. Robert Place and Dr. Moorim Kang, develops therapies that use small activating RNAs (saRNA) to up‑regulate targeted endogenous genes. The company has built an SCAD delivery system designed to improve biodistribution in extrahepatic tissues and claims a pipeline of first‑in‑class candidate medicines for unmet genetic disorders. Ractigen is a late‑stage preclinical company focused on advancing multiple programs toward clinical development. It is scaling oligonucleotide manufacturing capabilities to support progression of programs. The company closed an additional Series A+ financing to fund these development and manufacturing plans. All information here is sourced from the provided article.